B-cell malignancies - Network of Cancer Research

Parsaclisib is an Orally Active PI3Kδ Inhibitor for B-cell Malignancies Research

Phosphoinositide 3-kinases (PI3Ks), are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.…

autoimmune disease B-cell malignancies

BGB-8035 is an Orally Active BTK Inhibitor for B-cell Malignancies and Immunology Research

Louis Gilman June 19, 2023

Bruton tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in carcinogenic signaling. Meanwhile, it plays a central role in the signal transduction of B cell antigen…

B-cell malignancies

NX-2127 is an Orally and Potent BTK Inhibitor for B-cell Malignancies Research

Louis Gilman May 15, 2023

BTK (Bruton's tyrosine kinase), is a Tec family tyrosine kinase. It plays a crucial role in B cell development and function. BTK has dual regulatory functions in B cell apoptosis, such…

Parsaclisib is an Orally Active PI3Kδ Inhibitor for B-cell Malignancies Research

BGB-8035 is an Orally Active BTK Inhibitor for B-cell Malignancies and Immunology Research

NX-2127 is an Orally and Potent BTK Inhibitor for B-cell Malignancies Research

You Missed

Erlotinib is an EGFR TKI for NSCLC and Pancreatic Cancer Research

Parsaclisib is an Orally Active PI3Kδ Inhibitor for B-cell Malignancies Research

Nilotinib is an Orally Active Bcr-Abl Tyrosine Kinase Inhibitor for CML Research

Temsirolimus is an mTOR Inhibitor for Kinds of Cancers Research